Pediatric acute lymphoblastic leukemia, version 2.2020

Patrick Brown, Hiroto Inaba, Colleen Annesley, Jill Beck, Susan Colace, Mari Dallas, Kenneth DeSantes, Kara Kelly, Carrie Kitko, Norman Lacayo, Nicole Larrier, Luke Maese, Kris Mahadeo, Ronica Nanda, Valentina Nardi, Vilmarie Rodriguez, Jenna Rossoff, Laura Schuettpelz, Lewis Silverman, Jessica SunWeili Sun, David Teachey, Victor Wong, Gregory Yanik, Alyse Johnson-Chilla, Ndiya Ogba

Research output: Contribution to journalReview articlepeer-review

Abstract

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.

Original languageEnglish (US)
Pages (from-to)81-112
Number of pages32
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume18
Issue number1
DOIs
StatePublished - 2020

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Pediatric acute lymphoblastic leukemia, version 2.2020'. Together they form a unique fingerprint.

Cite this